Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 5, 2024
Daily News
April 5, 2024
- Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
- MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
April 5, 2024
- Rohto, Mitsui to Buy Singapore’s Chinese Medicine Firm for SGD800 Million
April 5, 2024
- Nippon Shinyaku, MiNA Therapeutics Join Hands in Rare CNS Disorders
April 5, 2024
- Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…